Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
about
Role of Biomarkers in the Development of PARP InhibitorsImplications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation CarriersTranslational and clinical implications of the genetic landscape of prostate cancer.Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.PARP Inhibitors in Prostate Cancer.Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
P2860
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@en
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@nl
type
label
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@en
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@nl
prefLabel
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@en
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@nl
P2093
P2860
P356
P1476
Sustained Complete Response to ...... ostate Cancer - A Case Report.
@en
P2093
Gini F Fleming
Gladell P Paner
Russell Z Szmulewitz
P2860
P356
10.3389/FONC.2015.00169
P577
2015-07-22T00:00:00Z